查詢結果分析
來源資料
相關文獻
- C型肝炎病毒感染之細胞生物學、免疫控制及治療
- Efficacy of Peginterferon Alfa Plus Ribavirin Treatment for Chronic Hepatitis C Virus Infection in Cirrhotic Patients
- 合併感染C型肝炎及人類免疫不全病毒患者之評估與治療要點
- Hepatitis C Virus Genotypes: Clinical Relevance and Therapeutic Implications
- 慢性B型肝炎合併慢性C型肝炎治療之新契機
- 醫療尖銳物品扎傷追蹤調查
- 綜觀C型肝炎病毒
- Immunopathogenesis of Viral Hepatitis B and C
- Antibody to Hepatitis C Virus in Multitransfused Patients with β-Thalassemia Major
- Interferon-α Therapy for Children with Chronic Hepatitis C
頁籤選單縮合
題 名 | C型肝炎病毒感染之細胞生物學、免疫控制及治療=The Cell Biology, Immunological Control and Therapy of Hepatitis C Virus Infection |
---|---|
作 者 | 唐蘊慧; 簡姿娟; 謝東呈; | 書刊名 | 弘光學報 |
卷 期 | 61 2010.12[民99.12] |
頁 次 | 頁1-25 |
分類號 | 415.5332 |
關鍵詞 | C型肝炎病毒; 干擾素α; 雷巴威林; Hepatitis C virus; HCV; Interferon-α; Ribavirin; |
語 文 | 中文(Chinese) |
中文摘要 | C型肝炎病毒 (hepatitis C virus; HCV ) 感染是最常見的輸血性病毒感染,全世界約有三億人口 被感染,也是造成肝硬化及肝細胞癌的主因。目前C型肝炎之治療是以干擾素α與Ribavirin為主, 但其成功治癒率僅約為50%。因此,更有效及低副作用的新型治療藥物的研發是必需且急迫的。本文探討近來HCV病毒學的進展及瞭解病毒的生命週期和致病機轉以提供研發新型抗病毒製劑的參考。本文亦描述近期HCV流行病學、臨床表現及診斷檢驗的發展。 |
英文摘要 | Hepatitis C virus (HCV) infection is the most common chronic blood-borne viral infection affecting about 300 million people worldwide, and is a leading cause of liver cirrhosis and hepatocellular carcinoma. Currently, treatment is restricted to a combination of interferon-α and ribavirin, which leads to a successful outcome of only about 50% of patients. Therefore, new effective treatments with tolerable side-effect profiles are needed urgently. Herein, we review progress in HCV biology with respect to the life-cycle of virus, pathogenesis of infection and development of specific antiviral treatment. We also discuss recent advance in epidemiology, clinical manifestation, and diagnostics of HCV infection. |
本系統中英文摘要資訊取自各篇刊載內容。